Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
-
ACADEMIA Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
-
BUSINESS Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
-
REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
-
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
-
BUSINESS Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
-
ORGANIZATION JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
-
BUSINESS Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
-
BUSINESS AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
-
BUSINESS Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
-
REGULATORY MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
-
BUSINESS Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
-
BUSINESS Weber to Become CEO of Takeda in April
March 4, 2015
-
REGULATORY Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
-
BUSINESS Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
-
REGULATORY Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…